Antoine Yver - Jul 1, 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
EVP & Chairman of Development
Signature
/s/ Marella Thorell, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Jul 1, 2022
Transactions value $
-$45,797
Form type
4
Date filed
7/6/2022, 06:16 PM
Previous filing
Jun 21, 2022
Next filing
Jul 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Sale -$45.8K -9.1K -1.23% $5.03 731K Jul 1, 2022 Direct F1, F2
transaction CNTA Ordinary Shares Award $0 +100K +13.69% $0.00 831K Jul 1, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted shares and does not represent a discretionary trade by the Reporting Person.
F3 The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in 10 equal quarterly instalments with the first such quarterly vesting being on September 30, 2022.